https://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-incContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inchttps://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc#u19946Wed, 01 Jul 2026 09:16:16 +0000Biogen has agreed to acquire RayThera Inc. in a deal valued at $1 billion. The acquisition adds preclinical assets to Biogen's immunology pipeline. Investors have reacted positively to the news, contributing to a fresh 52-week high for Biogen shares.What's confirmed:Biogen agreed to acquire RayThera Inc. for $1 billion.The acquisition expands Biogen's immunology pipeline with preclinical assets.Biogen shares reached a new 52-week high following the announcement. https://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inchttps://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc#u14284Fri, 26 Jun 2026 11:47:13 +0000Biogen entered a definitive agreement on June 17, 2026, to acquire RayThera Inc. The deal provides Biogen with three preclinical anti-inflammatory assets and a portfolio of immune-modulating candidates. Payments include an upfront fee and future clinical or regulatory milestones.What's confirmed:Biogen entered a definitive agreement to acquire RayThera on June 17, 2026.The acquisition price is up to $1 billion.RayThera specializes in small molecule therapies for immunology.The deal adds three preclinical anti-inflammatory assets to Biogen's pipeline.The transaction value includes an upfro https://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inchttps://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc#u9643Tue, 23 Jun 2026 09:36:57 +0000Biogen will acquire San Diego-based RayThera to obtain three preclinical anti-inflammatory assets. The deal is backloaded and includes a lead candidate nearing clinical development. Biogen expects to close the transaction in the third quarter of 2026.What's confirmed:Biogen entered a definitive agreement to acquire RayThera for up to $1 billion.The acquisition includes three preclinical assets with anti-inflammatory activity.Biogen expects to close the transaction in the third quarter of 2026.Still unconfirmed:The most mature asset is expected to enter Phase 1 development in Q3.The deal is bac https://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inchttps://www.live-feeds.com/feed/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc#u5347Sat, 20 Jun 2026 02:01:28 +0000Biogen has entered a definitive agreement to acquire RayThera, a private San Diego biotechnology firm specializing in small molecule immunology therapies. The deal adds multiple preclinical assets to Biogen's pipeline, including a lead candidate. Biogen expects to close the transaction in the third quarter of 2026.What's confirmed:Biogen agreed to acquire RayThera Inc. for up to $1 billion.RayThera is a private biotechnology company focused on small molecule therapies in immunology.The acquisition includes multiple immunology assets, including a lead asset poised for Phase 1 development.B